Skip to main content

Table 2 Frequencies of circulating immune subsets in melanoma patients

From: Clinical significance of plasmacytoid dendritic cells and myeloid-derived suppressor cells in melanoma

Cell type Cell frequency (mean % - SD)* Dichotomization cut-off (%)* Patients with “high” cell levels (%)
Dendritic cells (DC) 1.54 (0.54)   
  Plasmacytoid DCs 0.34 (0.18) 0.2515 66.7
  Myeloid DCs 0.96 (0.40)   
Myeloid-derived suppressor cells (MDSC) 4.00 (2.29) 4.13 33.3
  Monocytic MDSC 2.94 (2.81)   
  Polymorphonuclear MDSC 1.04 (0.64)   
CD3+ cells 43.60 (9.32) 40.25 68.2
  Cytotoxic T-cell 14.79 (6.06)   
  Regulatory T-cell 4.77 (1.35)   
  CTLA-4 expression by Tregs 92.32 (4.01) 93.7 37.3
  1. DC, dendritic cell; MDSC, myeloid-derived suppressor cell; Treg, regulatory T-cell; SD, standard deviation.
  2. * Percentage of live cells, except for Tregs (percentage of CD4+ cells).